Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Medivation Aims For 2010 Approval Of Alzheimer’s Drug Dimebon

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The neuroprotectant's novel mechanism of action makes it a good candidate for Alzheimer's disease drug cocktails, CEO Hung says.

You may also be interested in...



NTB Measure Gains Ground In Alzheimer's

Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.

NTB Measure Gains Ground In Alzheimer's

Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.

Industry Roundtable: Brains Behind Neurotech Discuss Innovation, Challenges Ahead

Neurotechnology Industry Organization Executive Director Zack Lynch and four neuroscience CEOs talk about issues facing the industry, including clinical trial design and funding development, during a roundtable discussion with “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

Medicare-Negotiated Drugs May Not Get Favorable Coverage In Part D: Will CMS Intervene?

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

See All
UsernamePublicRestriction

Register

PS066806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By